Caliper forms licensing pact with Agilent:
This article was originally published in Clinica
Executive Summary
Agilent Technologies has gained a non-exclusive licence to Caliper Life Sciences' microfluidics patent estate, which Agilent will use to develop clinical diagnostic applications for its 2100 Bioanalyser and 5100 automated lab-on-chip platform. In addition, the companies have entered into a five-year supply agreement, guaranteeing Caliper an exclusive licence to supply planar LabChip products for Agilent's 2100 Bioanalyser and future instrument platforms. Under the terms of the agreement, Agilent will pay Palo Alto-based Caliper an upfront licensing fee, plus royalties on future sales of diagnostic LabChip products covered under the agreement. The companies have not yet disclosed any further details of the two agreements.